Company
Ocular Therapeutix
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
0
Approvals since 2021
2
Originals and new uses
Phase 3 trials
13
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 313
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyPivotal-lookingRecruiting
Ocular Therapeutix, Inc.Industry
NCT07235085 · 930 participants (planned) · Start Nov 17, 2025 · Primary completion Mar 2027
Drug: Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24; Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 · For: Non-Proliferative Diabetic Retinopathy
Sites: Hagerstown, Maryland
Ocular Therapeutix, Inc.Industry
NCT07516132 · 850 participants (planned) · Start Apr 27, 2026 · Primary completion Aug 1, 2030
Drug: OTX-TKI · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Bakersfield, California; Santa Barbara, California; Waterford, Connecticut · 8 sites in all
Marketed drugs (1)
Newest FDA action first.
- Dextenza Dexamethasone · 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.